Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum-Sensitive Recurrent Ovarian Cancer


Bevacizumab (Bev) with Chemotherapy, Followed by Bev, in the Treatment of Newly Diagnosed and Platinum-Sensitive Recurrent Ovarian Cancer
Slides from presentations at ASCO 2011 and comments from Amit M Oza, MD and David R Spriggs, MD

Kristensen G et al. Result of interim analysis of overall survival in the GCIG ICON7 phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Proc ASCO 2011;Abstract LBA5006.

Dr Oza is Professor of Medicine at the University of Toronto, Co-Director of the Bras Family Drug Development Program and Director of the Cancer Clinical Research Unit at Princess Margaret Hospital in Toronto, Canada.